United States News All stories

Summit Therapeutics (NASDAQ:SMMT) announced the opening of a Phase 2 kidney cancer trial evaluating ivonescimab-based treatments in approximately 100 patients across two countries.

Veradermics (NYSE:MANE) reported positive Phase 3 results for VDPHL01, with both dosing regimens significantly increasing hair counts versus placebo after six months.

Cosmos Health (NASDAQ:COSM) forecasts approximately $15 million in fourth-quarter 2026 U.S. direct-to-consumer revenue, with projected gross profit of $10.5 million.

The forecast represents a 70% gross margin for its U.S. online business, compared with roughly 8% company-wide GAAP gross margin in Q2.

VinFast (NASDAQ:VFS) reported second-quarter 2026 revenue of $1.20 billion, up 85.5% year over year, supported by higher electric vehicle deliveries.

Peoples Bancorp of North Carolina (NASDAQ:PEBK) reported third-quarter 2026 net earnings of $5.7 million, up approximately 54% from $3.7 million a year earlier.

Alpha Tau Medical (NASDAQ:DRTS) received FDA authorization to expand its REGAIN brain cancer trial from 10 to 20 patients across three U.S. centers.

Eos Energy Enterprises (NASDAQ:EOSE) expects preliminary third-quarter 2026 revenue of US$82–US$83 million, representing 169%–172% growth from the prior year.

TCGX Acquisition Corp. (NASDAQ:TCGX) agreed to merge with TriGemX Bio in a transaction expected to generate approximately $246 million in gross proceeds.

Johnson & Johnson (NYSE:JNJ) reported 35% combined fistula remission at Week 48 with TREMFYA in its Phase 3 FUZION Crohn's disease trial.

Blackstone (NYSE:BX) closed its fifth energy transition private equity fund at US$8.7 billion, exceeding its predecessor's US$5.6 billion fundraising total by approximately 55%.

Dynex Capital (NYSE:DX) reported a negative 11.5% economic return for Q3 2026, as book value declined to $10.91 per share.

Merck (NYSE:MRK) agreed to acquire Silence Therapeutics (NASDAQ:SLN) for $20 per ADS, valuing its equity at approximately $1.3 billion.

Cytokinetics (NASDAQ:CYTK) received Health Canada approval for MYQORZO to treat adults with NYHA class II–III symptomatic obstructive hypertrophic cardiomyopathy, supported by 24-week trial results.

Mako Mining (NASDAQ:MAKO) recovered 12,743 ounces of gold in Q3 2026, generating approximately US$50 million in revenue from 11,581 ounces sold.

Chord Energy (NASDAQ:CHRD) reported preliminary third-quarter production of 290,500–290,900 barrels of oil equivalent daily, exceeding its guidance ceiling of 284,000 barrels.

AST SpaceMobile (NASDAQ:ASTS) welcomed a spectrum collaboration involving four European telecom operators, supporting its satellite connectivity strategy across a market exceeding 500 million subscribers.

Centrus Energy (NYSE:LEU) acquired Westerman Holdings for approximately $116 million, bringing manufacturing of centrifuge components into its operations.

EquipmentShare (NASDAQ:EQPT) raised its 2026 revenue forecast to $5.81–$6.05 billion, citing customer demand, fleet utilization and improving productivity.

EyePoint (NASDAQ:EYPT) announced plans to reduce its workforce by approximately 53%, targeting $30 million in annual savings following disappointing Phase 3 results.

Ardagh Group agreed to sell its approximately 42% stake in Trivium Packaging in a $3.4 billion transaction involving Silgan Holdings (NYSE:SLGN).

NRG Energy (NYSE:NRG) declared a quarterly cash dividend of $0.475 per common share, payable November 16, 2026, to shareholders of record November 2.

KKR (NYSE:KKR) agreed to sell Infinity Transportation to funds managed by Ares Management (NYSE:ARES) for approximately $2.9 billion in enterprise value.

CBIZ (NYSE:CBZ) reported third-quarter 2026 net income of $47 million, up 56.7%, as revenue increased 1.2% to $702 million.

Sunshine Silver Mining & Refining (NYSE:SSMR) completed approximately 47,600 meters of its 50,000-meter infill drilling program, advancing its planned Sunshine Mine restart in late 2028.